Tuesday, Amgen Inc (NASDAQ:AMGN) reported its fourth quarter 2023 adjusted net profit increased 15% to $4.71, beating the consensus of $4.62, driven by increased revenues, partially offset by higher operating expenses. For the fourth quarter, total revenues increased 20% to $8.2 billion, beating the consensus of $8.13 billion. Product sales grew 20%, driven by 23% volume growth, partially offset by a 3% lower net selling price. The performance included $954 million of sales from the recent Horizon Therapeutics acquisition between October 6 and December 31. Product sales were led by a 12% jump …